Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20,425 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cinobufotalin powerfully reversed EBV-miR-BART22-induced cisplatin resistance via stimulating MAP2K4 to antagonize non-muscle myosin heavy chain IIA/glycogen synthase 3β/β-catenin signaling pathway.
Liu Y, Jiang Q, Liu X, Lin X, Tang Z, Liu C, Zhou J, Zhao M, Li X, Cheng Z, Li L, Xie Y, Liu Z, Fang W. Liu Y, et al. Among authors: lin x. EBioMedicine. 2019 Oct;48:386-404. doi: 10.1016/j.ebiom.2019.08.040. Epub 2019 Oct 5. EBioMedicine. 2019. PMID: 31594754 Free PMC article.
Chemical compound cinobufotalin potently induces FOXO1-stimulated cisplatin sensitivity by antagonizing its binding partner MYH9.
Li Y, Liu X, Lin X, Zhao M, Xiao Y, Liu C, Liang Z, Lin Z, Yi R, Tang Z, Liu J, Li X, Jiang Q, Li L, Xie Y, Liu Z, Fang W. Li Y, et al. Among authors: lin z, lin x. Signal Transduct Target Ther. 2019 Nov 18;4:48. doi: 10.1038/s41392-019-0084-3. eCollection 2019. Signal Transduct Target Ther. 2019. PMID: 31754475 Free PMC article.
20,425 results
You have reached the last available page of results. Please see the User Guide for more information.